Targeted radiosensitization in prostate cancer
Ghotra VP, Geldof AA, Danen EH. Curr Pharm Des. 2013 Feb 19. [Epub ahead of print]

Source

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, the Netherlands. ghotravps@lacdr.leidenuniv.nl aa.geldof@vumc.nl.

Abstract

Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-kB(nuclear factor kappa-light-chain-enhancer of activated Bcells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.